Novartis Vaccines And Diagnostics Awarded Up To USD 220 Million By U.S. Department Of Health And Human Services For Development Of Cell Culture-Derived Influenza Vaccine

BASEL, Switzerland, May 4, 2006 (PRIMEZONE) -- Novartis announced today that the U.S. Department of Health and Human Services (HHS) has awarded Novartis Vaccines up to USD220 million to support the development of a cell culture-derived influenza vaccine, both to supply seasonal influenza vaccine and to respond rapidly in the event of an influenza pandemic. "Novartis is pleased to be working together with the U.S. government to provide a reliable vaccine supply for U.S. citizens and to further strengthen pandemic preparedness," said Dr. Daniel Vasella, Chairman and CEO of Novartis.

Back to news